Heterocyclic Amide Kinase Inhibitors for Selective p38α Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases, such as those associated with p38 kinase activity, often have limitations in selectively inhibiting p38α and β kinases, particularly in achieving proportional inhibition of p38α over p38β, which can impact efficacy in managing conditions like inflammatory bowel disease and rheumatoid arthritis.
Innovation Solution
Development of heterocyclic amide compounds that act as selective inhibitors of p38 kinase, particularly targeting p38α with higher selectivity than p38β, formulated into pharmaceutical compositions for administration to treat inflammatory disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used to inhibit p38 kinase activity, then inflammatory disease symptoms are reduced, but selectivity between p38α and p38β inhibition is insufficient
Solution Approach 1:
The patent applies local quality by designing heterocyclic amide compounds with specific molecular structures (Formula I) that exhibit differential binding affinity to p38α versus p38β kinase isoforms. The compounds contain specific heterocyclic rings (pyridine, pyrimidine, triazine) with particular substituent patterns that create localized interaction features preferentially recognized by p38α's active site, thereby achieving selective inhibition of p38α over p38β while maintaining overall p38 kinase inhibition capability
2Reliability
If heterocyclic amide compounds are designed for high p38α selectivity, then therapeutic efficacy for specific inflammatory conditions is improved, but compound structure complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying key molecular parameters of the heterocyclic amide core structure, including: (1) the type of heterocyclic ring (pyridine vs. pyrimidine vs. triazine), (2) the nature of substituents at positions R1-R6, (3) the length and saturation of alkylene chains, and (4) the stereochemistry at chiral centers. These parameter variations allow fine-tuning of the compounds' selectivity profile and potency, enabling optimization of therapeutic efficacy while managing structural complexity through rational design rather than random screening
Data Source
AI summary
A compound of Formula Iand enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.